Table 1.
Clinical profile, cardiovascular risk factors and therapies characterizing the subgroup of CAD patients enrolled on the study. Patients have been categorized for the presence of T2DM as a comorbidity
| CAD | CAD-T2DM | P value | |
|---|---|---|---|
| N | 15 | 17 | |
| AGE (years) | 65.33 ± 2.41 | 66.88 ± 2.31 | 0.65 |
| BMI (KG/m2) | 26.86 ± 0.87 | 27.13 ± 0.79 | 0.82 |
| Glycemia (mg/dL) | 103.1 ± 3.27 | 137.5 ± 10.31 | 0.004** |
| LDL (mg/dL) | 120.4 ± 11.52 | 78.40 ± 9.74 | 0.0095** |
| HDL (mg/dL) | 48.93 ± 3.58 | 45.60 ± 3.29 | 0.49 |
| Total cholesterol (mg/dL) | 189.1 ± 12.38 | 150.0 ± 9.67 | 0.012* |
| Creatinin(mg/dL) | 1.068 ± 0.1 | 1.096 ± 0.1 | 0.84 |
| Hypertension | 11 | 15 | |
| Dyslipidemia | 11 | 15 | |
| Smoke | 7 | 6 | |
| Oral antidiabetic agents | 0 | 14 | |
| Insulin | 0 | 1 | |
| Oral antidiabetic agents + Insulin | 0 | 2 | |
| Antihypertensive drugs | 12 | 15 | |
| Lipid-lowering drugs | 7 | 13 |
CAD ± T2DM, coronary artery disease with or without diabetes mellitus; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein. *P<0.05; **P<0.01 vs CAD